News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Woyach_Jennifer_OH_web.jpg)
CLL combo treatment: Phase-3 study inconclusive
- Author:
- Myles Starr
Results of the clinical trial of a CLL drug triplet therapy, presented at ASCO 2023, showed that more data are needed to determine its long-term...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Howlader_Nadia_MD_web.jpg)
New CLL meds: Improved survival rates, 1990-2018
- Author:
- Myles Starr
A just-published retrospective study shows nearly 30 years of steady progress in lengthening the lives of U.S. adults with CLL and other leukemias...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Andreadis_Charalambos_CA_web.jpg)
DLBCL: Major new treatment breakthroughs
- Author:
- Myles Starr
After decades of slow progress, new drugs and therapies are paving the way to more effective treatment of DLBCL.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Landgren_OlaC_FL_web.jpg)
Experts debate reducing ASCT for multiple myeloma
- Author:
- Myles Starr
Overall survival following multidrug regimens and transplant are on par, raising questions about the best frontline therapy for multiple myeloma...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Allan_John_NY_web.jpg)
Frontline CLL treatment: Avoiding adverse events
- Author:
- Myles Starr
Single-agent frontline therapy helps patients with CLL live longer, but those at high risk of relapse may benefit from multiagent treatment.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Furman_Richard_NY_web.jpg)
Relapsed CLL: New approaches prolong survival
- Author:
- Myles Starr
Venetoclax, with a second-generation generation Bruton’s tyrosine kinase inhibitor, can lead patients with relapsed CLL back to remission.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Munir_Tahla_ENGLAND_web.jpg)
MRD: Powerful metric for CLL research
- Author:
- Myles Starr
New study showed how leukemia specialists can harness measurable residual disease to gauge the efficacy of novel treatment options.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Cronin_ Robert_OH_web.jpg)
SCD meds: Why such ‘slow uptake’?
- Author:
- Myles Starr
A nationwide study found that pain medications approved to treat sickle cell disease were prescribed to fewer than one in three patients with SCD...
News
Black women have higher state-level rates of TNBC
- Author:
- Myles Starr
The state-level disparities highlight gaps in physicians’ understanding of how social factors contribute to disparities in TNBC risk.
News
Zika virus still calls for preparedness and vaccine development
- Author:
- Myles Starr
“There’s no antiviral that you can take for Zika. Until we have a vaccine, the key to controlling/preventing Zika is controlling the mosquitoes...
News
Radiotherapy for early breast cancer: Sharp cutoff at age 70
- Author:
- Myles Starr
Radiation therapy was 50% less likely to be prescribed for patients age 70 and older with early-stage breast cancer.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Jakubowiak_Andrzej_MD_IL_web.jpg)
Maintenance therapies boost MM survival rates
- Author:
- Myles Starr
Interim results in the phase 3 ATLAS trial seemed to buttress the benefits of intensive maintenance therapies for multiple myeloma, post...
News
Systematic review supports preferred drugs for HIV in youths
- Author:
- Myles Starr
Findings support the use of dolutegravir an raltegravir as part of WHO-recommended regimens for treating HIV.
News
Exciting advances in HR-positive breast cancer: Top five picks from SABCS
- Author:
- Myles Starr
Treatments meet unmet need and address unanswered questions.
News
Key research on TNBC: Top five picks from SABCS
- Author:
- Myles Starr
A study on the impact of platinum therapy on long-term TNBC outcomes ranks among the most popular.